2 results
Approved WMORecruiting
This amendment (extension to CRT-D subjects) aims to assess the economic effects of HM technology vs. classical follow-up of CRT-D patients from two perspectives: 1) the cost-effectiveness for the payer of health care, and 2) the economic impact on…
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…